UPDATE 1-Vivus, Auxilium sign $300 mln deal for erectile dysfunction drug
Oct 11 (Reuters) - Vivus Inc's erectile dysfunction drug will be marketed by Auxilium Pharmaceuticals Inc in the United States and Canada in a deal worth up to $300 million, including an upfront licensing fee of $30 million.
Auxilium said the deal would add to its earnings in 2015.
Vivus, known for its diet pill Qsymia, will be responsible for the initial supply and manufacturing of the oral drug, Stendra, Auxilium said in a statement.
The company said it expected to begin the commercial launch of the drug by the end of 2013 and start shipping the drug in December.
Vivus said the deal would help it tap the established sales network of Auxilium, which markets men's health products such as testosterone gel, Testim.
Stendra was approved by U.S. health regulators in April 2012.